

Press Release

Rodos BioTarget GmbH on the leap towards first clinical trials of its TargoSphere[®] technology platform

Hannover, Germany / June 11, 2014

Having successfully achieved key development milestones, the investors of Rodos BioTarget GmbH, a German biopharmaceutical company, have drawn an option. Within this frame, investors will furnish the company with fresh capital. This transaction has a value of more than EUR 1 m.

TargoSpheres[®] accommodate a wide range of active ingredients that are precisely shuttled into those cells of the human body where exerting their proper effect; for example, this allows for eliminating pathogens or enabling new or improved vaccinations. The developmental milestones realized mainly consisted in the preclinical validation of the company's TargoSphere[®] nanocarrier platform technology. Rodos BioTarget successfully completed all preclinical studies required for the approval of a first clinical trial. In addition, the production of both the targeting anchors that enable to recognize the target cells as well as of the complete TargoSphere[®] carriers have been industrially upscaled according to international GMP standards. Thus, the technology is clinically applicable.

About Rodos BioTarget (RBT)

According to the company's mission statement, *'To become the industry leader in targeted drug delivery by providing TargoSphere[®] nanocarriers for enabling significantly enhanced prophylactic and therapeutic approaches against devastating diseases'*, Rodos BioTarget GmbH is consequently developing its TargoSphere[®] technology platform. Being both highly tolerable for the patients as well as environmentally compliant, these nanocarriers can shuttle potent active ingredients and vaccines exactly into predefined target cells. By allowing to address different cell types by employing diverse targeting anchor, TargoSpheres[®] are of great interest for the pharmaceutical industry: Suitable active agents can now for the first time be delivered directly to their site of action and thus help to solve problems in the control of infections, cancers and autoimmune diseases. In addition, TargoSpheres[®] allow to re-define already established active ingredients for making them more effective and/or less burdened with side-effects. RBT specifically focuses on the development of antibacterial and antiviral applications under the names TargoBiotics[®] and TargoVir[®] that shall also be used for combating multi-resistant germs. For additional information, please see www.biotargeting.eu

Contact: Dr. M. Furch (CEO), + 49 176 3921 3096 and Dr. R. Gieseler-von der Crone (CSO), +49 176 6292 9350 / Rodos BioTarget GmbH / info@biotargeting.eu